Insights from the COORDINATE-Diabetes Trial

Key Takeaways

The trial focused on improving cardiovascular risk management in type 2 diabetes through a coordinated care model.
Structured care pathways and multidisciplinary teams were key interventions to enhance guideline adherence.
Results showed improved adherence to cardiovascular risk management guidelines among trial participants.
Future opportunities involve expanding the model to other chronic conditions and integrating technology for better patient engagement.

A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.

EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

EP: 2.Strategies for Prevention and Screening of CRM Conditions

EP: 3.The Link Between Obesity and CRM Conditions

EP: 4.Challenges in Managing Co-Morbid CRM Conditions

EP: 5.Contemporary Guidelines for CRM Conditions

EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions

EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions

EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM

EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines

EP: 10.Care Coordination for High-Risk CRM Patients

EP: 11.Takeaways from the UH CINEMA Program

EP: 12.Exploring the Kidney-CHAMP Study

Now Viewing

EP: 13.Insights from the COORDINATE-Diabetes Trial

Video content above is prompted by the following:

Tell us about the COORDINATE-Diabetes trial.
What were the objectives of COORDINATE-Diabetes and how was the trial designed?
What interventions were provided?
What were the results of the study?
What are future opportunities to improve CRM care based on this trial?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.